ASGCT Citeline Q3 2023 Report_hero
Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.
Darkened Qualified calendar. Please allow all cookies to use functionality.

To enable the booking feature, please enable all cookies in your browser.